Cargando…
Discovery and Evaluation of Entry Inhibitors for SARS-CoV-2 and Its Emerging Variants
The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the coronavirus disease 19 (COVID-19) pandemic. Despite unprecedented research and developmental efforts, SARS-CoV-2-specific antivirals are still unavailable for the treatment of COVID-19. In most instan...
Autores principales: | Acharya, Arpan, Pandey, Kabita, Thurman, Michellie, Klug, Elizabeth, Trivedi, Jay, Sharma, Kalicharan, Lorson, Christian L., Singh, Kamal, Byrareddy, Siddappa N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8610590/ https://www.ncbi.nlm.nih.gov/pubmed/34550770 http://dx.doi.org/10.1128/JVI.01437-21 |
Ejemplares similares
-
Screening of Botanical Drugs against Lassa Virus Entry
por: Liu, Yang, et al.
Publicado: (2021) -
Evasion of a Human Cytomegalovirus Entry Inhibitor with Potent Cysteine Reactivity Is Concomitant with the Utilization of a Heparan Sulfate Proteoglycan-Independent Route of Entry
por: Murray, M. J., et al.
Publicado: (2020) -
Screening and Identification of Lassa Virus Entry Inhibitors from an FDA-Approved Drug Library
por: Wang, Peilin, et al.
Publicado: (2018) -
Sertraline Is an Effective SARS-CoV-2 Entry Inhibitor Targeting the Spike Protein
por: Chen, Yuliu, et al.
Publicado: (2022) -
A Novel Attenuated Enterovirus A71 Mutant with VP1-V238A,K244R Exhibits Reduced Efficiency of Cell Entry/Exit and Augmented Binding Affinity to Sulfated Glycans
por: Meng, Tao, et al.
Publicado: (2021)